Yeji

$ALNY

ALNYLAM PHARMACEUTICALS, INC.

Runway:cash-flow +
NasdaqMarket cap: —CIK 0001178670

Upcoming catalysts

0 surfaced

No catalysts surfaced for ALNY yet.

Drug pipeline

onpattro
amvuttra
oxlumo
patisiran
cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis
vutrisiran
inclisiran
elevated LDL-C / ASCVD
ALN-HSD
Nonalcoholic Steatohepatitis
ALN-4324
Type 2 Diabetes Mellitus (T2DM)
ALN-VSP02
Solid Tumors
ALN-AAT02
ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
ALN-AAT
Antitrypsin Deficiency Liver Disease
ALN-TTR01
Transthyretin Mediated Amyloidosis (ATTR)
ALN-AGT01
Hypertension
ALN-2232
Obesity
Zilebesiran
High Cardiovascular Risk
ALN-TTRSC (revusiran) for subcutaneous administration
TTR-mediated Amyloidosis
Nucresiran
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
Lumasiran
PH1
ALN-TTRSC (revusiran)
TTR-mediated Amyloidosis
ALN-PCSSC
Hypercholesterolemia
ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
TTR-mediated Amyloidosis
ALN-XDH
Gout
ALN-HTT02
Huntington's Disease
ALN-4915
Healthy Volunteers
ALN-6400
Von Willebrand Disease (VWD)
ALN-TTR02
TTR-mediated Amyloidosis
Cemdisiran
Atypical Hemolytic Uremic Syndrome
Standard of Care
Hereditary Amyloidosis, Transthyretin-Related
Placebo
Cerebral Amyloid Angiopathy
ALN-AGT01 RVR
Healthy Volunteers
ALN-APP
Early-Onset Alzheimer Disease
Revusiran
Transthyretin (TTR)-Mediated Amyloidosis
ALN-TTRSC04
Transthyretin-Mediated Amyloidosis
Indapamide
Hypertension
ALN-TTRSC02
Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
ALN-KHK
Type 2 Diabetes Mellitus (T2DM)
givosiran (ALN-AS1)
Acute Intermittent Porphyria
ALN-4285
Healthy Volunteers
ALN-RSV01
Respiratory Syncytial Virus Infections
ALN-5288
Alzheimer's Disease
ALN-CC5
Paroxysmal Nocturnal Hemoglobinuria (PNH)
ALN-BCAT
Advanced Hepatocellular Carcinoma
ALN-PCS02
Elevated LDL-Cholesterol (LDL-C)
ALN-HBV
Hepatitis B
Givosiran
Acute Hepatic Porphyria
patisiran (ALN-TTR02)
TTR-mediated Amyloidosis
Revusiran (ALN-TTRSC)
TTR-mediated Amyloidosis
ALN-6222
Obesity

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT04561518——Recruiting2033-12-31
NCT07358078——Recruiting2030-10-23
NCT05040373——Recruiting2030-10-12
NCT07181109ZilebesiranPhase 3Recruiting2030-09-30
NCT07052903NucresiranPhase 3Recruiting2030-05-28
NCT07214727ALN-5288Phase 1Recruiting2030-03-06
NCT05231785ALN-APPPhase 1Recruiting2029-04-20
NCT04982393——Active Not Recruiting2028-09-01
NCT06585449ALN-HTT02Phase 1Recruiting2028-07-05
NCT07553442ALN-AGT01 RVRPhase 2Recruiting2028-04-01
NCT06679946vutrisiranPhase 3Enrolling By Invitation2028-03-31
NCT06659640ALN-6400Phase 2Recruiting2028-01-05
NCT07223203NucresiranPhase 3Recruiting2027-12-27
NCT07624071ALN-6222Phase 1Not Yet Recruiting2027-12-14
NCT06360289Standard of Care—Active Not Recruiting2027-12-01
NCT06600321ALN-BCATPhase 1Recruiting2027-09-30
NCT06845202ALN-4324Phase 2Recruiting2027-08-31
NCT06393712PlaceboPhase 2Recruiting2027-08-09
NCT07535606ALN-4915Phase 1Recruiting2027-07-31
NCT07575308ALN-6400Phase 2Not Yet Recruiting2027-06-30

Recent catalysts

FDA approvalMar 20, 2025· 443d ago· success
$ALNYALNYLAM PHARMACEUTICALS, INC.
amvuttra
“openFDA SUPPL (EFFICACY) approval of AMVUTTRA — application NDA215515”
CRLOct 9, 2023· 971d ago
$ALNYALNYLAM PHARMACEUTICALS, INC.
patisiran · cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis
“On October 9, 2023, Alnylam Pharmaceuticals, Inc. issued a press release...announcing receipt of a Complete Response Letter from the United States Food and Drug Administration in regard to the Company's supplemental new drug application for patisiran, an investigational RNAi therapeutic for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.”
PDUFAOct 8, 2023· 972d ago
$ALNYALNYLAM PHARMACEUTICALS, INC.
patisiran · cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis
“the FDA has set an action date of October 8, 2023 under the Prescription Drug User Fee Act.”
AdComSep 13, 2023· 997d ago
$ALNYALNYLAM PHARMACEUTICALS, INC.
onpattro
“a meeting of the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration has been scheduled for September 13, 2023, to review the Company's supplemental New Drug Application for ONPATTRO ® (patisiran) as a potential treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis”
FDA approvalJan 13, 2023· 1240d ago· success
$ALNYALNYLAM PHARMACEUTICALS, INC.
onpattro
“openFDA SUPPL (EFFICACY) approval of ONPATTRO — application NDA210922”
FDA approvalOct 6, 2022· 1339d ago· success
$ALNYALNYLAM PHARMACEUTICALS, INC.
oxlumo
“openFDA SUPPL (EFFICACY) approval of OXLUMO — application NDA214103”
PDUFAJul 14, 2022· 1423d ago· unknown
$ALNYALNYLAM PHARMACEUTICALS, INC.
vutrisiran
“The updated Prescription Drug User Fee Act action date to allow for this review is July not14, 2022.”
FDA approvalJun 13, 2022· 1454d ago· success
$ALNYALNYLAM PHARMACEUTICALS, INC.
amvuttra
“openFDA ORIG (TYPE 1) approval of AMVUTTRA — application NDA215515”
PDUFAJan 1, 2022· 1617d ago
$ALNYALNYLAM PHARMACEUTICALS, INC.
inclisiran · elevated LDL-C / ASCVD
“Leqvio is now approved in more than 45 countries, with most awaiting reimbursement, and remains on track for U.S. launch with FDA action date of January 1, 2022.”